Advert for Healthcare Professionals Only
I am a patient (Please go to our patient website)
- All Topics
- Allergy and Clinical Immunology
- Anesthesiology
- Angiology
- Cardiology
- Central Nervous System
- Clinical Laboratory
- Complementary and Alternative Medicine
- Critical Care/Intensive Care
- Dermatology
- Diabetes and Endocrinology
- Ear, Nose and Throat
- Emergency Medicine
- Eye Health and Disorders
- Family Medicine
- Gastroenterology
- Gerontology/Geriatrics
- Haematology
- Hepatology
- HIV/AIDS
- Immunology
- Infectious Diseases
- Internal Medicine
- Kidney and Urological Diseases
- Medical Genetics
- Men's Health, Andrology and Urology
- Musculoskeletal Disorders
- Neonatal/Perinatal Medicine
- Neurological Disorders
- Nutrition and Dietetics
- Oncology
- Orthopaedics
- Paediatrics
- Pain Management
- Palliative Medicine
- Plastic Surgery and Aesthetic Medicine
- Podiatry
- Preventive Medicine
- Psychiatry/Mental Health
- Radiology
- Respiratory
- Rheumatology
- Sexual Health
- Sleep Medicine
- Sports Medicine
- Surgery (General)
- Transplantation
- Tropical Medicine
- Vaccines
- Women's Health and Obs/Gyn
- ADHD
- Alzheimer's Disease
- Arthritis
- Atopic Dermatitis
- Cholesterol
- Chronic Myeloid Leukemia
- COPD
- Cystic Fibrosis
- Diabetes
- Gastrointestinal Stromal Tumours
- Hepatitis
- Hypertension
- Insomnia
- Lysosomal Storage Disorders
- Men's Health
- Multiple Sclerosis
- Niemann-Pick type C
- NSCLC
- Opioids and Pain
- Parkinson's Disease
- Post-Myocardial Infarction
- Prostate Cancer
- Renal Anaemia
- Renal Cell Carcinoma
- Soft Tissue Sarcoma
- Third Party Website - Asthma and COPD
- CAPOZIDE TABLETS
- SURMONTIL 10MG AND 25MG TABLETS
- NAPRATEC OP
- COBALIN-H INJECTION
- CARBEX
- CALCIUM RESONIUM 99.934% W/W POWDER FOR ORAL/RECTAL SUSPENSION
- HYPURIN BOVINE ISOPHANE
- HYPURIN BOVINE LENTE
- HYPURIN PORCINE 30/70 MIX CARTRIDGES
- HYPURIN BOVINE ISOPHANE VIALS
- DUKORAL ORAL CHOLERA VACCINE
- OXYNORM LIQUID 5 MG/5 ML ORAL SOLUTION
- DORZOLAMIDE/TIMOLOL EYE DROPS
- FENOFIBRATE 267MG CAPSULES
- TRACRIUM INJECTION
- EXOCIN
- FRAGMIN - TREATMENT OF VTE
- FLUDARABINE PHOSPHATE 50 MG POWDER FOR SOLUTION FOR INJECTION OR INFUSION
- GABITRIL FILM-COATED TABLETS (5 , 10, 15 MG)
- PROTOPIC 0.03% OINTMENT
- XISMOX 60 XL PROLONGED RELEASE TABLETS
- PALLADONE SR CAPSULES
- ZINERYT
- PURI-NETHOL 50 MG TABLETS
- DAKTACORT OINTMENT
- MYLERAN 2 MG FILM-COATED TABLETS
- NEOTIGASON 10MG CAPSULES
- LEUKERAN TABLETS 2 MG
- LANVIS TABLETS 40 MG
- PROVIGIL 100 MG TABLETS, PROVIGIL 200 MG TABLETS
- ADHD
- Alzheimers
- Anxiety Disorders
- Arthritis
- Asthma
- Avonex
- Breast Cancer
- Cervical Cancer
- Cholesterol
- Colorectal Cancer
- Copaxone
- Depression
- Diabetes
- Erectile Dysfunction
- Extavia
- Hypertension
- Insomnia
- Men's Health
- Meningitis
- Migraine
- Pain Management
- Parkinson's
- Pharma News
- Post-MI
- Pregnancy
- Prostate
- Rebif
- Renal anaemia
- Renal Cell Carcinoma
- Thrombosis
- Thromboembolism
- Tysabri
Advert for Healthcare Professionals Only
Latest Drugs
Kidney and Urological Diseases Drug Data - A-Z (English)
Drug Class Description
Imidazole antifungals.Generic Name
Clotrimazole - genital infectionsDrug Description
Pessary or cream.Presentation
Vaginal tablet, clotrimazole 500mg. Cream, clotrimazole 1%.Indications
Cream: Treatment of skin infections due to dermatophytes (eg, trichophyton species), yeasts (eg, candida species), moulds and other fungi. These include ringworm (tinea) infections, athlete's foot, paronychia, pityriasis versicolor, erythrasma and intertrigo, as well as fungal nappy rash, candidal vaginitis and candidal balanitis. Pessary: Treatment of candidal vaginitis.Adult Dosage
Cream: apply to the affected area two or three times daily. Treat for at least two weeks for Candida infections. Pessary: One vaginal tablet inserted in the evening. If external symptoms (eg, discharge, itching) have not subsided completely within three days after termination of therapy, after termination of therapy, treatment should be continued only after consulting the attending doctor.
Child Dosage
Cream: As above. Pessary: under 16 years, only on doctor's directions.Contra Indications
Hypersensitivity to clotrimazole. Pessary: only to be used in children under 16 years on advice of the doctor; first trimester of pregnancy.
Special Precautions
Pregnancy and lactation. If pessary is used during pregancy, use without an applicator.Interactions
Cream: None known. Pessary: clotrimazole reduces the efficacy of other drugs which are used to treat fungal diseases (amphotericin and other polyene antibiotics, eg, nystatin).
Adverse Reactions
Rarely, burning or irritation immediately after application. Hypersensitivity reactions.Manufacturer
AkitaDrug Availability
(P)Updated
15 April 2009Advert for Healthcare Professionals Only
Related News
Toviaz(Pfizer) success in Overactive Bladder in Older Patients Kidney and Urological Diseases Page
Toviaz (fesoterodine fumarate) from Pfizer has met its primary endpoint in Study A0221049.This was a 12 week trial which enrolled 562 patients aged 65 or older who were randomised to either fesoterodine or placebo. Toviaz was found to be statistically significantly superior to placebo in reducing the mean number of urgency urinary incontinence episodes per day at the end of treatment for Overactive Bladder. While the prevalence of overactive bladder increases with age, limited research has been conducted in older individuals with this condition. Toviaz, a muscarinic antagonist, is approved in both the USA and EU to treat the symptoms of Overactive Bladder.
FDA approves Anturol (Watson Pharma) for Overactive Bladder treatment Kidney and Urological Diseases Page
FDA has approved Anturol (oxybutynin) from Antares Pharma/Watson Pharma as a topical gel 3% for the treatment of Overactive Bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency. The active ingredient is delivered transdermally, and not metabolized by the liver in the same way as orally administered oxybutynin. This results in a low level of side effects, such as dry mouth and constipation. Under an exclusive licensing agreement, Watson anticipates launching the product in 2012.
